affymetrix : wo führt der weg hin - 500 Beiträge pro Seite
eröffnet am 03.06.05 14:34:21 von
neuester Beitrag 28.01.09 10:48:22 von
neuester Beitrag 28.01.09 10:48:22 von
Beiträge: 65
ID: 985.336
ID: 985.336
Aufrufe heute: 0
Gesamt: 10.970
Gesamt: 10.970
Aktive User: 0
ISIN: US00826T1088 · WKN: 901198
12,301
EUR
-0,06 %
-0,007 EUR
Letzter Kurs 02.04.16 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,6000 | +57,48 | |
| 1,9200 | +23,87 | |
| 5,4500 | +19,00 | |
| 6,9300 | +17,46 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,3600 | -13,49 | |
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 2,2900 | -17,63 | |
| 2,2600 | -30,25 |
Feedback
wie geht`s bei affymetrix weiter? bisher ist sie kontinuierlich nach oben gelaufen. geht es noch weiter nach oben ?
Schwache Zahlen 2 Q hintereinander, aber auf alle Fälle nach rsi, fast stoch, stoch rsi usw. gnadenlos über-verkauft und ein Kandidat für einen Rebound.
Hi,
ruhig hier.
Keiner mehr an der Affy interessiert.
auris
ruhig hier.
Keiner mehr an der Affy interessiert.
auris
Affymetrix geht davon aus, im vierten Quartal lediglich einen Umsatz von 15 Millionen Dollar erzielt zu haben. Dies liegt unterhalb der von dem Unternehmen bisher abgegebenen Prognose. Der Entwickler von biotechnologischem Analysegerät teilte mit, dass die Instrumenten-Verkäufe überraschend schleppend verlaufen seien. Zudem sei es bei einem großen Analyse-Dienstleistungsauftrag zu Verzögerungen gekommen.
Es handelt sich dabei bereits um die zweite Umsatzwarnung, die Affymetrix abgegeben hat. Bereits im Oktober hatte das Unternehmen seine Umsatzprognose für das vierte Quartal zurückschrauben müssen
Es handelt sich dabei bereits um die zweite Umsatzwarnung, die Affymetrix abgegeben hat. Bereits im Oktober hatte das Unternehmen seine Umsatzprognose für das vierte Quartal zurückschrauben müssen
Hallo ale,
weiß jemand, warum die Affymetrix heute ohne news über 13% fällt?
das Eregebnis für das 4. Quartal wird doch erst am 26.01.2006 veröffentlicht.
BG
auris
weiß jemand, warum die Affymetrix heute ohne news über 13% fällt?
das Eregebnis für das 4. Quartal wird doch erst am 26.01.2006 veröffentlicht.
BG
auris
Trading Spotlight
Danke Gony,
ich habe nichts an News gefunden.
BG
auris
ich habe nichts an News gefunden.
BG
auris
Affymetrix Issues 2nd Warning for 4Q
Thursday January 5, 6:05 pm ET
Affymetrix Issues Second Warning for Fourth-Quarter Revenue; Shares Drop 12.5 Percent
SANTA CLARA, Calif. (AP) -- Affymetrix Inc. on Thursday reported disappointing sales of its biotechnology instruments will push fourth-quarter revenue below previous expectations, marking the second such warning during this period.
Shares of the Santa Clara-based company plunged $5.88, or 12.5 percent, to $41.02 in after-hours activity on the INET electronic exchange, after the stock closed at $46.90 on the Nasdaq.
Affymetrix said it now expects, based on preliminary financial data, that product and related revenue for the quarter ended Dec. 31 will be roughly $15 million below previous guidance. Sales for those products are now targeted at about $105 million, while total revenue would fall to $108 million.
Wall Street had expected the company to report earnings of 38 cents per share on sales of $122.8 million during the quarter, according to analysts polled by Thomson Financial. Analysts will likely have to make yet another adjustment to consensus views before earnings are scheduled to be reported on Jan. 26.
In October, the company said sales would fall $10 million below previous expectations to $120 million, with total sales hitting $123 million. At the time, Affymetrix said it was unable to produce enough of its gene-analysis equipment.
A month earlier, Affymetrix warned Wall Street that third-quarter sales would fall by $10 million to $12 million because of an inability to produce a microchip used in genetic research and drug development. The company`s third quarter profit then tumbled 44 percent.
Despite the warning, the company said strong demand through 2006 is expected to help boost profit going forward.
"Affymetrix is experiencing growing pains as it both innovates and commercializes new products in high potential markets," said Stephen P.A. Fodor, the company`s founder, chairman and CEO. "We are carrying record orders into 2006 and expect to achieve around 15 percent top-line growth for the full-year."
Grüße
Thursday January 5, 6:05 pm ET
Affymetrix Issues Second Warning for Fourth-Quarter Revenue; Shares Drop 12.5 Percent
SANTA CLARA, Calif. (AP) -- Affymetrix Inc. on Thursday reported disappointing sales of its biotechnology instruments will push fourth-quarter revenue below previous expectations, marking the second such warning during this period.
Shares of the Santa Clara-based company plunged $5.88, or 12.5 percent, to $41.02 in after-hours activity on the INET electronic exchange, after the stock closed at $46.90 on the Nasdaq.
Affymetrix said it now expects, based on preliminary financial data, that product and related revenue for the quarter ended Dec. 31 will be roughly $15 million below previous guidance. Sales for those products are now targeted at about $105 million, while total revenue would fall to $108 million.
Wall Street had expected the company to report earnings of 38 cents per share on sales of $122.8 million during the quarter, according to analysts polled by Thomson Financial. Analysts will likely have to make yet another adjustment to consensus views before earnings are scheduled to be reported on Jan. 26.
In October, the company said sales would fall $10 million below previous expectations to $120 million, with total sales hitting $123 million. At the time, Affymetrix said it was unable to produce enough of its gene-analysis equipment.
A month earlier, Affymetrix warned Wall Street that third-quarter sales would fall by $10 million to $12 million because of an inability to produce a microchip used in genetic research and drug development. The company`s third quarter profit then tumbled 44 percent.
Despite the warning, the company said strong demand through 2006 is expected to help boost profit going forward.
"Affymetrix is experiencing growing pains as it both innovates and commercializes new products in high potential markets," said Stephen P.A. Fodor, the company`s founder, chairman and CEO. "We are carrying record orders into 2006 and expect to achieve around 15 percent top-line growth for the full-year."
Grüße
06.01.2006 13:00:00 (BUSINESS WIRE)
versenden drucken > vor
3 Datensätze gefunden.
Perlegen Forms Collaboration With Genentech in Cancer Genetics
Perlegen Sciences, Inc. announced today that it has begun a collaboration with Genentech, Inc. (NYSE
NA) to study the genetics of cancer. Findings from the study could potentially be applied to the discovery and development of targeted medicines and molecular diagnostics for the disease. Perlegen`s high throughput oligonucleotide array approach utilizes Affymetrix (Nasdaq:AFFX) GeneChip(R) technology.
Anzeige:
Langfristiger Vermögensaufbau - Staatliche Förderung schafft bis zu 75% Abschreibung! Jetzt informieren!
Cancer is the second leading cause of death in the United States. It has been estimated that approximately one-half of all men and one-third of all women will develop some form of cancer during their lifetimes. An improved understanding of the genetics of cancer may enable the development of novel therapeutics and diagnostic tests for cancer, as well as better targeting of cancer treatments to responsive patient populations.
Terms of the agreement were not disclosed.
"We look forward to applying Perlegen`s expertise to further our understanding of the important role genetics plays in cancer," said David Cox, M.D., Ph.D., Chief Scientific Officer of Perlegen. "We are proud to collaborate with Genentech, a recognized leader in oncology therapeutics and pioneer in targeted therapies for cancer patients."
About Perlegen
Perlegen Sciences, Inc. is working to provide safer and more effective drugs to consumers. The company can quickly and cost effectively analyze millions of genetic variations in DNA samples and use this information to explain and predict the efficacy and adverse effect profiles of prescription drugs. In doing so, Perlegen strives to bring drugs to the market that might otherwise have been discontinued in clinical development. Perlegen also applies its expertise to discovering genetic variations associated with disease for potential new therapeutics and diagnostics. For years, scientists and drug manufacturers have been eager to comprehensively examine entire genomes; through Perlegen, this is now possible.
Based in Mountain View, California, Perlegen was formed in late 2000 as a spin-off from Affymetrix, Inc. For more information about the company and its technologies, visit Perlegen`s website at www.perlegen.com.
Perlegen Sciences, Perlegen, and the Perlegen logo are trademarks of Perlegen Sciences, Inc.
Quelle: BUSINESS WIRE
versenden drucken > vor
3 Datensätze gefunden.
Perlegen Forms Collaboration With Genentech in Cancer Genetics
Perlegen Sciences, Inc. announced today that it has begun a collaboration with Genentech, Inc. (NYSE
NA) to study the genetics of cancer. Findings from the study could potentially be applied to the discovery and development of targeted medicines and molecular diagnostics for the disease. Perlegen`s high throughput oligonucleotide array approach utilizes Affymetrix (Nasdaq:AFFX) GeneChip(R) technology.Anzeige:
Langfristiger Vermögensaufbau - Staatliche Förderung schafft bis zu 75% Abschreibung! Jetzt informieren!
Cancer is the second leading cause of death in the United States. It has been estimated that approximately one-half of all men and one-third of all women will develop some form of cancer during their lifetimes. An improved understanding of the genetics of cancer may enable the development of novel therapeutics and diagnostic tests for cancer, as well as better targeting of cancer treatments to responsive patient populations.
Terms of the agreement were not disclosed.
"We look forward to applying Perlegen`s expertise to further our understanding of the important role genetics plays in cancer," said David Cox, M.D., Ph.D., Chief Scientific Officer of Perlegen. "We are proud to collaborate with Genentech, a recognized leader in oncology therapeutics and pioneer in targeted therapies for cancer patients."
About Perlegen
Perlegen Sciences, Inc. is working to provide safer and more effective drugs to consumers. The company can quickly and cost effectively analyze millions of genetic variations in DNA samples and use this information to explain and predict the efficacy and adverse effect profiles of prescription drugs. In doing so, Perlegen strives to bring drugs to the market that might otherwise have been discontinued in clinical development. Perlegen also applies its expertise to discovering genetic variations associated with disease for potential new therapeutics and diagnostics. For years, scientists and drug manufacturers have been eager to comprehensively examine entire genomes; through Perlegen, this is now possible.
Based in Mountain View, California, Perlegen was formed in late 2000 as a spin-off from Affymetrix, Inc. For more information about the company and its technologies, visit Perlegen`s website at www.perlegen.com.
Perlegen Sciences, Perlegen, and the Perlegen logo are trademarks of Perlegen Sciences, Inc.
Quelle: BUSINESS WIRE
Hi alle,
der Kurs hat sich heute ( - 14% auf - 7,6& ) doch noch etwas erholt.
Verstehe echt die Panik mancher Leute nicht.
Warten wir mal ab, wo der Kurs in ein paar Jahren steht.
BG
auris
der Kurs hat sich heute ( - 14% auf - 7,6& ) doch noch etwas erholt.
Verstehe echt die Panik mancher Leute nicht.
Warten wir mal ab, wo der Kurs in ein paar Jahren steht.
BG
auris
Scheiße.
Ich bekomme langsam einen Affen mit Affy.
- 11%
Ich bekomme langsam einen Affen mit Affy.
- 11%
Schlußkurs nur noch - 4,8% 30,5 Euro
Die 30er Marke müsste doch vorerst halten...
Ergo:Rebound Speku!
Gruss B.
Hallo Buddah,
ich hoffe es.
Meine Affymetrix hatte sich von ca. - 80% auf - 30% erholt.
Danach ging es in großen Schritten abwärts. Zuvor jedoch in großen Schritten aufwärts.
Jedoch möchte ich sie nicht verkaufen.
Devise lautet; Top pder Flop.
Warum fällt Affymetrix so, Buddah?
Finde keine neuen NEWS.
Wenigstens haben sich meine anderen Bios bis jetzt erholt.
BG
auris
ich hoffe es.
Meine Affymetrix hatte sich von ca. - 80% auf - 30% erholt.
Danach ging es in großen Schritten abwärts. Zuvor jedoch in großen Schritten aufwärts.
Jedoch möchte ich sie nicht verkaufen.
Devise lautet; Top pder Flop.
Warum fällt Affymetrix so, Buddah?
Finde keine neuen NEWS.
Wenigstens haben sich meine anderen Bios bis jetzt erholt.
BG
auris
Ich denke das waren Gewinnmitnahmen,kombiniert mit Abstufungen.
Merrill Lynch zB. meint:
10.03.2006 07:49:12 - AKTIENCHECK.DE
Affymetrix "sell"
Rating-Update: Die Analysten von Merrill Lynch stufen die Aktie von Affymetrix (ISIN US00826T1088/ WKN 901198) unverändert mit "sell" ein. Es sei mit einem geringeren Umsatzwachstum zu rechnen.
mich reizt auch lediglich ein "kleiner Rebound Zock"
Gehebelt versteht sich:
WKN: GS0GAE
(bin aber noch nicht drinnen)
Gruss B.
Merrill Lynch zB. meint:
10.03.2006 07:49:12 - AKTIENCHECK.DE
Affymetrix "sell"
Rating-Update: Die Analysten von Merrill Lynch stufen die Aktie von Affymetrix (ISIN US00826T1088/ WKN 901198) unverändert mit "sell" ein. Es sei mit einem geringeren Umsatzwachstum zu rechnen.
mich reizt auch lediglich ein "kleiner Rebound Zock"
Gehebelt versteht sich:
WKN: GS0GAE
(bin aber noch nicht drinnen)
Gruss B.
Danke Buddah,
auf die Analysten gebe ich nicht viel.
Die meisten Börsianer haben auch Angst vor April(Nai Saison.
Affy kann man eh nicht nach den 3 Signalen (Berechnung W. Buffett) berechnen.
Das klappt nur mit stockkonservativen Titeln.
Affy bleibt in meinem Depot. Basta. Ich habe notfalls noch 10-15 JAhre Zeit.
BG
auris
auf die Analysten gebe ich nicht viel.
Die meisten Börsianer haben auch Angst vor April(Nai Saison.
Affy kann man eh nicht nach den 3 Signalen (Berechnung W. Buffett) berechnen.
Das klappt nur mit stockkonservativen Titeln.
Affy bleibt in meinem Depot. Basta. Ich habe notfalls noch 10-15 JAhre Zeit.
BG
auris
aurisinterna
sind doch auch ein potentieller Übernahmekandidat,oder?
Gruss B.
sind doch auch ein potentieller Übernahmekandidat,oder?
Gruss B.
Hat jemand News?
Diese Meldung vom 19.7.06 könnte der Auslöser gewesen sein
Affymetrix hat heute Preissenkungen für sein 500K SNP System angekündigt. Die Anwendung, mit deren Hilfe Medikamenten-Kandidaten auf ihre Wirksamkeit überprüft werden können, sollen künftig nur noch in Zweier-Kombination angeboten werden und dann zusammen 250 Dollar kosten. Der ursprüngliche Verkaufspreis für das System wurde nicht bekannt gegeben. Ein UBS-Analyst hat diesen aber heute mit rund 750 Dollar beziffert.
Beobachter gehen davon aus, dass der Preisschritt durch ein Konkurrenzprodukt des Herstellers Illumina erzwungen worden ist. Dieses System weist offenbar eine deutlich höhere Testleistung auf. Affymetrix wiederum hat angekündigt, im ersten Quartal 2007 seinerseits ein SNP-Produkt mit dem doppelten der bisherigen Leistung auf den Markt zu bringen.
Affymetrix hat heute Preissenkungen für sein 500K SNP System angekündigt. Die Anwendung, mit deren Hilfe Medikamenten-Kandidaten auf ihre Wirksamkeit überprüft werden können, sollen künftig nur noch in Zweier-Kombination angeboten werden und dann zusammen 250 Dollar kosten. Der ursprüngliche Verkaufspreis für das System wurde nicht bekannt gegeben. Ein UBS-Analyst hat diesen aber heute mit rund 750 Dollar beziffert.
Beobachter gehen davon aus, dass der Preisschritt durch ein Konkurrenzprodukt des Herstellers Illumina erzwungen worden ist. Dieses System weist offenbar eine deutlich höhere Testleistung auf. Affymetrix wiederum hat angekündigt, im ersten Quartal 2007 seinerseits ein SNP-Produkt mit dem doppelten der bisherigen Leistung auf den Markt zu bringen.
Antwort auf Beitrag Nr.: 22.844.258 von Drahtzieher am 21.07.06 17:02:06Top oder Flop.
Affy bleibt im Depot.
Ich glaube trotzdem noch an eine Wende.
Was stark steigen kann, kann auch stark fallen und...
Geduld mit allen Bios.
auris
Affy bleibt im Depot.
Ich glaube trotzdem noch an eine Wende.
Was stark steigen kann, kann auch stark fallen und...
Geduld mit allen Bios.
auris
Antwort auf Beitrag Nr.: 23.270.214 von aurisinterna am 01.08.06 17:00:53Hallo ,
wie immer niemand hier;-)
Die Amis sind nicht so blöd wie die zittrigen Deutschen.
USA nur - 8%.
Immer gut, wenn sich niemand für eine Aktie interessiert.
BG
auris
wie immer niemand hier;-)
Die Amis sind nicht so blöd wie die zittrigen Deutschen.
USA nur - 8%.
Immer gut, wenn sich niemand für eine Aktie interessiert.
BG
auris
also bin dick in affx und bleibe dabei,,,,affx hat schon oft schwierige situationen gemeistert und ich denke das wird ihnen auch diesmal gelingen, ich weiss nicht warum, aber wenn die zahlen schlecht aufgenommen werden , schicken die Amis die Aktien mehrere tage hintereinander ins Minus, siehe ESLR und BRCM
Heute + 2,53 %
Was ist los bei Affymetrix,
werde 1 paar Stück nachlegen
Was ist los bei Affymetrix,
werde 1 paar Stück nachlegen
Antwort auf Beitrag Nr.: 23.486.544 von lucky am 17.08.06 18:58:41Hi to all,
Affy what is happend?
auris;-)
Affy what is happend?
auris;-)
Nutzung des Threads sollte wieder möglich sein.
ComMOD
ComMOD
Antwort auf Beitrag Nr.: 33.891.014 von ComMOD am 15.04.08 18:42:02Fein, das der Thread wieder offen ist.
Hat jemand einen Schimmer warum die Aktie so einbricht??? Wegen der 3 % Umsatzreduktion??? Wenn ja, dann kann man nur sagen, kaufen was das Zeug haelt.
Hat jemand einen Schimmer warum die Aktie so einbricht??? Wegen der 3 % Umsatzreduktion??? Wenn ja, dann kann man nur sagen, kaufen was das Zeug haelt.
Antwort auf Beitrag Nr.: 33.891.070 von Gruenspan59 am 15.04.08 18:48:42die amis sind mal wieder gnadenlos
hier zu den hintergründen
Affymetrix Misses; Investors Panic
By Brian Orelli April 15, 2008
That's gotta hurt. After Affymetrix (Nasdaq: AFFX) lowered its 2008 revenue guidance by about 3% yesterday evening, to a range of $490 million to $510 million, its stock opened more than 35% lower today. I guess in this market, any perceived weakness is an excuse to cut and run.
The Motley Fool Rule Breakers pick also announced estimated first-quarter revenue of $80 million, excluding the $90 million payment from Illumina (Nasdaq: ILMN) to settle the companies' lawsuit. That means revenues were essentially flat for the first quarter year over year. And that's not something a company can get away with if, like Affymetrix yesterday, its trailing price-to-earnings ratio is approaching 100.
The biochip maker blamed the fall in revenues on decreased spending on research and development among pharmaceutical companies. The R&D drop shouldn't be a big surprise, given all of the layoffs we've been hearing about in recent weeks from the likes of Wyeth (NYSE: WYE) and Schering-Plough (NYSE: SGP). And it certainly doesn't bode well for other companies, such as Invitrogen (Nasdaq: IVGN) and QIAGEN (Nasdaq: QGEN), which sell laboratory supplies to companies.
Affymetrix's biggest weakness is that its revenue stream isn't terribly diversified -- even its most recent acquisition of USB didn't make it less dependent on companies and universities purchasing laboratory supplies, although the purchase did broaden its offerings. It's supplying its machines to Laboratory Corp. of America (NYSE: LH) to provide clinical diagnostics and is developing companion genetic tests to be used in combination with drugs, but Affymetrix hasn't come close to reaching its full potential in clinical diagnostics. In a few years, Affymetrix should be able to ride the R&D spending waves much more easily.
Investors will get to see full financial results and hear the company's plan for the future at next week's conference call. If it can hit its new revenue guidance for the year, it'll still have year-over-year revenue growth of 8%-13% excluding this year's one-time gain. If it can cut costs to make up the lower top-line growth, Affymetrix should be OK this year.
hier zu den hintergründen
Affymetrix Misses; Investors Panic
By Brian Orelli April 15, 2008
That's gotta hurt. After Affymetrix (Nasdaq: AFFX) lowered its 2008 revenue guidance by about 3% yesterday evening, to a range of $490 million to $510 million, its stock opened more than 35% lower today. I guess in this market, any perceived weakness is an excuse to cut and run.
The Motley Fool Rule Breakers pick also announced estimated first-quarter revenue of $80 million, excluding the $90 million payment from Illumina (Nasdaq: ILMN) to settle the companies' lawsuit. That means revenues were essentially flat for the first quarter year over year. And that's not something a company can get away with if, like Affymetrix yesterday, its trailing price-to-earnings ratio is approaching 100.
The biochip maker blamed the fall in revenues on decreased spending on research and development among pharmaceutical companies. The R&D drop shouldn't be a big surprise, given all of the layoffs we've been hearing about in recent weeks from the likes of Wyeth (NYSE: WYE) and Schering-Plough (NYSE: SGP). And it certainly doesn't bode well for other companies, such as Invitrogen (Nasdaq: IVGN) and QIAGEN (Nasdaq: QGEN), which sell laboratory supplies to companies.
Affymetrix's biggest weakness is that its revenue stream isn't terribly diversified -- even its most recent acquisition of USB didn't make it less dependent on companies and universities purchasing laboratory supplies, although the purchase did broaden its offerings. It's supplying its machines to Laboratory Corp. of America (NYSE: LH) to provide clinical diagnostics and is developing companion genetic tests to be used in combination with drugs, but Affymetrix hasn't come close to reaching its full potential in clinical diagnostics. In a few years, Affymetrix should be able to ride the R&D spending waves much more easily.
Investors will get to see full financial results and hear the company's plan for the future at next week's conference call. If it can hit its new revenue guidance for the year, it'll still have year-over-year revenue growth of 8%-13% excluding this year's one-time gain. If it can cut costs to make up the lower top-line growth, Affymetrix should be OK this year.
Antwort auf Beitrag Nr.: 33.891.070 von Gruenspan59 am 15.04.08 18:48:42sk in usa 10,95 25mio shares umgesetzt
Antwort auf Beitrag Nr.: 33.893.344 von roofy am 15.04.08 22:32:12
Unglaublichwas hier abgelaufen ist. Das Volumen ist Wahnsinn.
Da werden Einige eindecken müssen. Der Wert ist billiger als
vor 10 Jahren...
Unglaublichwas hier abgelaufen ist. Das Volumen ist Wahnsinn.
Da werden Einige eindecken müssen. Der Wert ist billiger als
vor 10 Jahren...
Hall0,
habe mich gestern bei den Amis eingedeckt.
Die News ist lächerlich und der Markt hat übertrieben,gehe heute bei den Amis von Kursen zwischen 12-14 Dollar aus minimum.
habe mich gestern bei den Amis eingedeckt.
Die News ist lächerlich und der Markt hat übertrieben,gehe heute bei den Amis von Kursen zwischen 12-14 Dollar aus minimum.
Antwort auf Beitrag Nr.: 33.895.323 von hiasi am 16.04.08 10:02:14Der Beitrag von Roofy ist sehr interessant, sagt mir aber eigentlich niocht alles aus, wie es tatsaechlich um die Firma steht. So wie ich es verstanden habe, ist es eigentlich gar nicht so schlecht. Um so verwunderlicher ist der doch sehr krasse Absturz. Denke mal dass sich die Aktie wieder deutlich erholen wird. Für mich eion klarer Kauf, was ich auch gestern gemacht habe.
Glueck allen Investierten.
Glueck allen Investierten.
Antwort auf Beitrag Nr.: 33.895.503 von Iseki am 16.04.08 10:18:29Iseki,
Richtig, sehe den Kurssturz mehr als übertrieben. Gutes Zeichen war in Amiland zu Börsenende, dass der Kurs wieder gestiegen ist.
Richtig, sehe den Kurssturz mehr als übertrieben. Gutes Zeichen war in Amiland zu Börsenende, dass der Kurs wieder gestiegen ist.
Da werden sich einige eindecken müssen,
sehe ich genauso der Verkauf war gestern voll übertrieben,
Die Amis können jetzt mal darüber schlafen und werden feststellen das 35% Minus nicht gerecht fertig sind.
sehe ich genauso der Verkauf war gestern voll übertrieben,
Die Amis können jetzt mal darüber schlafen und werden feststellen das 35% Minus nicht gerecht fertig sind.
Antwort auf Beitrag Nr.: 33.895.560 von Iseki am 16.04.08 10:23:12Schon alleine vom KGV her betrachtet ist die Firma sehr günstig bewertet. Denke mal die Amis werden heute wieder verstärkt kaufen.
Ich habe gstern in der 2 Updown Welle zu geschlagen, der Kursanstieg zum Handelsende hat gezeigt wo der Kurs heute hin geht.
Antwort auf Beitrag Nr.: 33.895.577 von Gruenspan59 am 16.04.08 10:25:18Unter Aktiencheck.de sind einige Einstufungen zu Affymetrix. Alle nicht so besonders schlecht. Hier eine davon:
Affymetrix "buy"
16.04.2008
Deutsche Bank Securities
Rating-Update:
Frankfurt (aktiencheck.de AG) - Die Analysten von Deutsche Bank Securities stufen die Aktie von Affymetrix (ISIN US00826T1088 / WKN 901198) unverändert mit "buy" ein. Das Kursziel werde von 28 auf 19,50 USD gesenkt. (16.04.2008/ac/a/u)
---------
Von den 19,50 Dollar sind wir weit entfernt!!!
Affymetrix "buy"
16.04.2008
Deutsche Bank Securities
Rating-Update:
Frankfurt (aktiencheck.de AG) - Die Analysten von Deutsche Bank Securities stufen die Aktie von Affymetrix (ISIN US00826T1088 / WKN 901198) unverändert mit "buy" ein. Das Kursziel werde von 28 auf 19,50 USD gesenkt. (16.04.2008/ac/a/u)
---------
Von den 19,50 Dollar sind wir weit entfernt!!!
Antwort auf Beitrag Nr.: 33.895.582 von Iseki am 16.04.08 10:25:38Ich habe auch gestern zugegriffen, ist auch heute noch verlockend!
Antwort auf Beitrag Nr.: 33.895.503 von Iseki am 16.04.08 10:18:29
Vielleicht nicht heute. Aber inden nächsten Tagen möglich.
Vielleicht nicht heute. Aber inden nächsten Tagen möglich.
Antwort auf Beitrag Nr.: 33.895.648 von Gruenspan59 am 16.04.08 10:31:47Wieviel Stücke hast du gekauft?
Antwort auf Beitrag Nr.: 33.895.682 von Iseki am 16.04.08 10:34:45Na ja, schon ein paar. Allerdings Millionär werde ich damit auf keinen Fall. 
Antwort auf Beitrag Nr.: 33.896.141 von Gruenspan59 am 16.04.08 11:11:19Vorboerslich scheint es gar nicht so schlecht aus zu sehen!
Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
10.95 0 (0.00) 0 10.94 (9) 11.55 (4)
Quelle:
freerealtime.com
Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
10.95 0 (0.00) 0 10.94 (9) 11.55 (4)
Quelle:
freerealtime.com
Antwort auf Beitrag Nr.: 33.896.141 von Gruenspan59 am 16.04.08 11:11:19geht schon ziemlich hoch vorbörslich
08:09:30 Q 11.35 +0.40 4,400
08:08:42 Q 11.35 +0.40 300
08:08:35 Q 11.40 +0.45 200
08:08:29 Q 11.35 +0.40 300
08:07:56 Q 11.31 +0.36 1,000
08:07:39 Q 11.26 +0.31 500
08:00:02 Q 11.07 +0.12 350
08:00:00 Q 11.26 +0.31 200
08:00:00 Q 11.26 +0.31 300
07:33:00 Q 11.07 +0.12 163
08:09:30 Q 11.35 +0.40 4,400
08:08:42 Q 11.35 +0.40 300
08:08:35 Q 11.40 +0.45 200
08:08:29 Q 11.35 +0.40 300
08:07:56 Q 11.31 +0.36 1,000
08:07:39 Q 11.26 +0.31 500
08:00:02 Q 11.07 +0.12 350
08:00:00 Q 11.26 +0.31 200
08:00:00 Q 11.26 +0.31 300
07:33:00 Q 11.07 +0.12 163
Antwort auf Beitrag Nr.: 33.898.259 von roofy am 16.04.08 14:32:33Lohnt da noch ein Einstieg??
Antwort auf Beitrag Nr.: 33.898.330 von Bioperle am 16.04.08 14:38:47schwer zu sagen
seit dem tiefpunkt gestern sind das schon 10%
allerdings wurde das teil schon schwer verprügelt und wird sich noch etwas erholen
ob der das nachhaltig sein wird ist fraglich
seit dem tiefpunkt gestern sind das schon 10%
allerdings wurde das teil schon schwer verprügelt und wird sich noch etwas erholen
ob der das nachhaltig sein wird ist fraglich
Antwort auf Beitrag Nr.: 33.898.330 von Bioperle am 16.04.08 14:38:47Wenn ich von den Kurszielen der Analysten ausgehe, der Schlechteste sagt 19 Dollar, dann auf jeden Fall.
Antwort auf Beitrag Nr.: 33.898.626 von Gruenspan59 am 16.04.08 15:06:17
Viel ist nicht grade passiert. Nach dem Absturz nicht mal
ein satter Bounce. Vielleicht kommt der noch.
Viel ist nicht grade passiert. Nach dem Absturz nicht mal
ein satter Bounce. Vielleicht kommt der noch.
Antwort auf Beitrag Nr.: 33.898.626 von Gruenspan59 am 16.04.08 15:06:17Insider Transaktionen:
6-Feb-08 FODOR STEPHEN P A
Officer 75,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 KING KEVIN M
Officer 24,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 GIBSON JAMES R II
Officer 2,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 CAULFIELD BARBARA A
Officer 9,200 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 BATTY JOHN
Officer 9,200 Direct Acquisition (Non Open Market) at $0 per share. N/A
8-Jan-08 KING KEVIN M
Officer 3,803 Direct Disposition (Non Open Market) at $22.69 per share. $86,290
18-Oct-07 CAULFIELD BARBARA A
Officer 2,250 Direct Automatic Sale at $28 per share. $63,000
28-Aug-07 LOUCKS VERNON R JR
Director 20,132 Direct Sale at $22.65 - $22.99 per share. $459,0002
28-Aug-07 LOUCKS VERNON R JR
Director 3,200 Direct Sale at $23 - $23.03 per share. $74,0002
8-Aug-07 KING KEVIN M
Officer 12,000 Direct Sale at $27.33 per share. $327,960
9-Jul-07 CAULFIELD BARBARA A
Officer 10,000 Direct Option Exercise at $19.34 - $19.34 per share. $193,0002
9-Jul-07 CAULFIELD BARBARA A
Officer 10,000 Direct Automatic Sale at $26 - $26 per share. $260,0002
8-Jul-07 KING KEVIN M
Officer 6,541 Direct Disposition (Non Open Market) at $25.58 - $25.58 per share. $167,0002
18-Jun-07 BATTY JOHN
Officer 30,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
15-Jun-07 CAULFIELD BARBARA A
Officer 10,000 Direct Option Exercise at $19.34 - $19.34 per share. $193,0002
15-Jun-07 CAULFIELD BARBARA A
Officer 10,000 Direct Automatic Sale at $26 - $26 per share. $260,0002
13-Jun-07 TRICE ROBERT H
Director 4,547 Direct Acquisition (Non Open Market) at $0 per share. N/A
13-Jun-07 YOUNG JOHN A
Director 4,547 Direct Acquisition (Non Open Market) at $0 per share. N/A
13-Jun-07 WAYMAN ROBERT PAUL
Director 4,547 Direct Acquisition (Non Open Market) at $0 per share. N/A
6-Feb-08 FODOR STEPHEN P A
Officer 75,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 KING KEVIN M
Officer 24,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 GIBSON JAMES R II
Officer 2,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 CAULFIELD BARBARA A
Officer 9,200 Direct Acquisition (Non Open Market) at $0 per share. N/A
5-Feb-08 BATTY JOHN
Officer 9,200 Direct Acquisition (Non Open Market) at $0 per share. N/A
8-Jan-08 KING KEVIN M
Officer 3,803 Direct Disposition (Non Open Market) at $22.69 per share. $86,290
18-Oct-07 CAULFIELD BARBARA A
Officer 2,250 Direct Automatic Sale at $28 per share. $63,000
28-Aug-07 LOUCKS VERNON R JR
Director 20,132 Direct Sale at $22.65 - $22.99 per share. $459,0002
28-Aug-07 LOUCKS VERNON R JR
Director 3,200 Direct Sale at $23 - $23.03 per share. $74,0002
8-Aug-07 KING KEVIN M
Officer 12,000 Direct Sale at $27.33 per share. $327,960
9-Jul-07 CAULFIELD BARBARA A
Officer 10,000 Direct Option Exercise at $19.34 - $19.34 per share. $193,0002
9-Jul-07 CAULFIELD BARBARA A
Officer 10,000 Direct Automatic Sale at $26 - $26 per share. $260,0002
8-Jul-07 KING KEVIN M
Officer 6,541 Direct Disposition (Non Open Market) at $25.58 - $25.58 per share. $167,0002
18-Jun-07 BATTY JOHN
Officer 30,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
15-Jun-07 CAULFIELD BARBARA A
Officer 10,000 Direct Option Exercise at $19.34 - $19.34 per share. $193,0002
15-Jun-07 CAULFIELD BARBARA A
Officer 10,000 Direct Automatic Sale at $26 - $26 per share. $260,0002
13-Jun-07 TRICE ROBERT H
Director 4,547 Direct Acquisition (Non Open Market) at $0 per share. N/A
13-Jun-07 YOUNG JOHN A
Director 4,547 Direct Acquisition (Non Open Market) at $0 per share. N/A
13-Jun-07 WAYMAN ROBERT PAUL
Director 4,547 Direct Acquisition (Non Open Market) at $0 per share. N/A
Antwort auf Beitrag Nr.: 33.898.626 von Gruenspan59 am 16.04.08 15:06:17
TOP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
PRIMECAP MANAGEMENT COMPANY 5,714,755 8.28 $132,239,430 31-Dec-07
MAZAMA CAPITAL MANAGEMENT, INC 5,202,447 7.54 $120,384,623 31-Dec-07
MANNING & NAPIER ADVISORS INC 3,908,367 5.66 $90,439,612 31-Dec-07
Barclays Global Investors UK Holdings Ltd 3,545,998 5.14 $82,054,393 31-Dec-07
Legg Mason Capital Management, Inc. 3,334,050 4.83 $77,149,917 31-Dec-07
MORGAN STANLEY 2,809,413 4.07 $65,009,816 31-Dec-07
VANGUARD GROUP, INC. (THE) 2,251,475 3.26 $52,099,131 31-Dec-07
Capital Research Global Investors 2,000,000 2.90 $46,280,000 31-Dec-07
FMR LLC 10,157,695 14.71 $235,049,062 31-Dec-07
PRICE (T.ROWE) ASSOCIATES INC 7,196,840 10.43 $166,534,877 31-Dec-07
TOP MUTUAL FUND HOLDERS
Holder Shares % Out Value* Reported
PRICE (T.ROWE) MID CAP GROWTH FUND 3,500,000 5.07 $80,990,000 31-Dec-07
VANGUARD HORIZON FUND-CAPITAL OPPORTUNITY PORTFOLIO 3,105,500 4.50 $71,861,270 31-Dec-07
LEGG MASON SPECIAL INVESTMENT TRUST, INC. 2,928,000 4.24 $67,753,920 31-Dec-07
GROWTH FUND OF AMERICA INC 2,000,000 2.90 $46,280,000 31-Dec-07
Capital Research Global Investors 2,000,000 2.90 $46,280,000 31-Dec-07
EQ ADVISORS TRUST-EQ/ALLIANCE COMMON STOCK PORTFOLIO 1,722,949 2.50 $39,869,039 31-Dec-07
FIDELITY GROWTH COMPANY FUND 6,903,190 10.00 $138,477,991 31-Jan-08
PRICE (T.ROWE) MID-CAP VALUE FUND 1,109,000 1.61 $25,662,260 31-Dec-07
ALGER MIDCAP GROWTH INSTITUTIONAL PORTFOLIO 990,850 1.44 $25,227,041 31-Oct-07
PRICE (T.ROWE) NEW HORIZONS FUND 875,000 1.27 $20,247,500 31-Dec-07
View Transactions for Insiders & Institutional Holders
TOP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
PRIMECAP MANAGEMENT COMPANY 5,714,755 8.28 $132,239,430 31-Dec-07
MAZAMA CAPITAL MANAGEMENT, INC 5,202,447 7.54 $120,384,623 31-Dec-07
MANNING & NAPIER ADVISORS INC 3,908,367 5.66 $90,439,612 31-Dec-07
Barclays Global Investors UK Holdings Ltd 3,545,998 5.14 $82,054,393 31-Dec-07
Legg Mason Capital Management, Inc. 3,334,050 4.83 $77,149,917 31-Dec-07
MORGAN STANLEY 2,809,413 4.07 $65,009,816 31-Dec-07
VANGUARD GROUP, INC. (THE) 2,251,475 3.26 $52,099,131 31-Dec-07
Capital Research Global Investors 2,000,000 2.90 $46,280,000 31-Dec-07
FMR LLC 10,157,695 14.71 $235,049,062 31-Dec-07
PRICE (T.ROWE) ASSOCIATES INC 7,196,840 10.43 $166,534,877 31-Dec-07
TOP MUTUAL FUND HOLDERS
Holder Shares % Out Value* Reported
PRICE (T.ROWE) MID CAP GROWTH FUND 3,500,000 5.07 $80,990,000 31-Dec-07
VANGUARD HORIZON FUND-CAPITAL OPPORTUNITY PORTFOLIO 3,105,500 4.50 $71,861,270 31-Dec-07
LEGG MASON SPECIAL INVESTMENT TRUST, INC. 2,928,000 4.24 $67,753,920 31-Dec-07
GROWTH FUND OF AMERICA INC 2,000,000 2.90 $46,280,000 31-Dec-07
Capital Research Global Investors 2,000,000 2.90 $46,280,000 31-Dec-07
EQ ADVISORS TRUST-EQ/ALLIANCE COMMON STOCK PORTFOLIO 1,722,949 2.50 $39,869,039 31-Dec-07
FIDELITY GROWTH COMPANY FUND 6,903,190 10.00 $138,477,991 31-Jan-08
PRICE (T.ROWE) MID-CAP VALUE FUND 1,109,000 1.61 $25,662,260 31-Dec-07
ALGER MIDCAP GROWTH INSTITUTIONAL PORTFOLIO 990,850 1.44 $25,227,041 31-Oct-07
PRICE (T.ROWE) NEW HORIZONS FUND 875,000 1.27 $20,247,500 31-Dec-07
View Transactions for Insiders & Institutional Holders
mMn wurde der Wert aufgrund der Umsatz/Erlös Rücknahme viel zu extrem abgestraft. Aktuell auf 9 Jahrestief. Vielleicjht pack ich mir mal ein paar Anteile lanfristig ins Depot
Jemand ne Info über deren gegenwärtige finanzielle Situation? Cashbestand etc.?
thanx
b.
Jemand ne Info über deren gegenwärtige finanzielle Situation? Cashbestand etc.?
thanx
b.
Antwort auf Beitrag Nr.: 33.928.563 von ballard1 am 20.04.08 18:21:46Pathwork® Tissue of Origin Test to be Offered Through CLIA-Certified Laboratory
Company Website: http://www.affymetrix.com
SANTA CLARA, Calif. -- (Business Wire)
Affymetrix Inc. (Nasdaq:AFFX) today announced that Pathwork Diagnostics Inc. will begin offering a molecular diagnostic test based on the Affymetrix microarray platform. The Pathwork Tissue of Origin Test is one of the first microarray-based diagnostic tests for cancer in the United States. The test is being made available through the recently CLIA-certified Pathwork® Diagnostics Laboratory.
There are an estimated 200,000 patients with uncertain primary tumors, including Cancer of Unknown Primary, in the U.S. each year.1,2,3 One study concluded that in particularly challenging cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools.4 The Pathwork Tissue of Origin Test is designed to help oncologists determine the primary site of a metastatic tumor with greater certainty.
“The Affymetrix technology enabled us to develop a test that uses the power of genomic information to aid in the diagnosis of uncertain tumors,” said Deborah J. Neff, president and chief executive officer of Pathwork Diagnostics. “Ultimately, we believe the Pathwork Tissue of Origin Test will improve patient outcomes while saving the healthcare system money. We can now offer the test through our CLIA-certified laboratory and we are actively working with the FDA to obtain clearance that will allow us to also offer a diagnostic kit directly to clinical laboratories.”
“Affymetrix is partnering with innovative molecular diagnostic companies like Pathwork Diagnostics to bring about new diagnostic tests that can provide more efficient and complete methods to better diagnose, classify and manage complex diseases like cancer,” said Kevin King, president of Affymetrix. “Affymetrix offers the only microarray instrumentation system that has been cleared for molecular diagnostic laboratories in the U.S. and E.U., and we continue to work with our partners to further facilitate this broad adoption of array-based diagnostic tests and help make personalized medicine a reality.”
Affymetrix is the only company to offer a continuous path to discover, develop and commercialize complex biomarker signature assays. The company partners with the leading diagnostic companies through its Powered by Affymetrix™ (PbA) program. The Affymetrix GeneChip® System 3000Dx is the only microarray instrumentation platform to receive regulatory clearance by the U.S. FDA and to be CE marked in the European Union for in vitro diagnostic use. The CLIA-certified Affymetrix Clinical Services Laboratory (ACSL) offers microarray-based molecular diagnostic patient and clinical trial testing services that enable customers to leverage Affymetrix’ technology and experience to bring more effective molecular diagnostic tests to patients faster than ever before. There are currently more than 20 different molecular assay tests based on the Affymetrix platform under development by Affymetrix and its 11 PbA Partners.
About Affymetrix
Affymetrix GeneChip®microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 12,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’“expectations,”“beliefs,”“hopes,”“intentions,”“strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement with Pathwork® Diagnostics Tissue of Origin Test discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
1 Pavlidis N, Fizazi K. Cancer of Unknown Primary (CUP). Critical Reviews in Oncology/Hematology. 2005;54:243-250.
2 Tong KB, Murtagh KN, Hubert HB, et al. Incidence, costs of care and survival of Medicare beneficiaries diagnosed with carcinoma of unknown primary (CUP). Poster presented at annual meeting of Association for Molecular Pathology; November 17, 2006; Orlando, FL.
3 Pathwork Diagnostics analysis.
4 Hillen HF. Unknown primary tumours. Postgrad Med J. 2000;76:690-693.
Contacts:
Company Website: http://www.affymetrix.com
SANTA CLARA, Calif. -- (Business Wire)
Affymetrix Inc. (Nasdaq:AFFX) today announced that Pathwork Diagnostics Inc. will begin offering a molecular diagnostic test based on the Affymetrix microarray platform. The Pathwork Tissue of Origin Test is one of the first microarray-based diagnostic tests for cancer in the United States. The test is being made available through the recently CLIA-certified Pathwork® Diagnostics Laboratory.
There are an estimated 200,000 patients with uncertain primary tumors, including Cancer of Unknown Primary, in the U.S. each year.1,2,3 One study concluded that in particularly challenging cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools.4 The Pathwork Tissue of Origin Test is designed to help oncologists determine the primary site of a metastatic tumor with greater certainty.
“The Affymetrix technology enabled us to develop a test that uses the power of genomic information to aid in the diagnosis of uncertain tumors,” said Deborah J. Neff, president and chief executive officer of Pathwork Diagnostics. “Ultimately, we believe the Pathwork Tissue of Origin Test will improve patient outcomes while saving the healthcare system money. We can now offer the test through our CLIA-certified laboratory and we are actively working with the FDA to obtain clearance that will allow us to also offer a diagnostic kit directly to clinical laboratories.”
“Affymetrix is partnering with innovative molecular diagnostic companies like Pathwork Diagnostics to bring about new diagnostic tests that can provide more efficient and complete methods to better diagnose, classify and manage complex diseases like cancer,” said Kevin King, president of Affymetrix. “Affymetrix offers the only microarray instrumentation system that has been cleared for molecular diagnostic laboratories in the U.S. and E.U., and we continue to work with our partners to further facilitate this broad adoption of array-based diagnostic tests and help make personalized medicine a reality.”
Affymetrix is the only company to offer a continuous path to discover, develop and commercialize complex biomarker signature assays. The company partners with the leading diagnostic companies through its Powered by Affymetrix™ (PbA) program. The Affymetrix GeneChip® System 3000Dx is the only microarray instrumentation platform to receive regulatory clearance by the U.S. FDA and to be CE marked in the European Union for in vitro diagnostic use. The CLIA-certified Affymetrix Clinical Services Laboratory (ACSL) offers microarray-based molecular diagnostic patient and clinical trial testing services that enable customers to leverage Affymetrix’ technology and experience to bring more effective molecular diagnostic tests to patients faster than ever before. There are currently more than 20 different molecular assay tests based on the Affymetrix platform under development by Affymetrix and its 11 PbA Partners.
About Affymetrix
Affymetrix GeneChip®microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 12,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’“expectations,”“beliefs,”“hopes,”“intentions,”“strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement with Pathwork® Diagnostics Tissue of Origin Test discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
1 Pavlidis N, Fizazi K. Cancer of Unknown Primary (CUP). Critical Reviews in Oncology/Hematology. 2005;54:243-250.
2 Tong KB, Murtagh KN, Hubert HB, et al. Incidence, costs of care and survival of Medicare beneficiaries diagnosed with carcinoma of unknown primary (CUP). Poster presented at annual meeting of Association for Molecular Pathology; November 17, 2006; Orlando, FL.
3 Pathwork Diagnostics analysis.
4 Hillen HF. Unknown primary tumours. Postgrad Med J. 2000;76:690-693.
Contacts:
kaum bin ich investiert gibts seit ner Woche keine Postings mehr.
Technische Reaktion nach dem Absturz bleib ja leider aus. Seh Affymetrix langfristig und geh von positiveren Kursen aus
Technische Reaktion nach dem Absturz bleib ja leider aus. Seh Affymetrix langfristig und geh von positiveren Kursen aus
nach aktuell erfolgter Konsolidierung kann es gerne wieder etwas höher gehen. Krass aus welchen Regionen Affymetrix kommt, wenn man sich mal nen Lnagfristchart anschaut
Antwort auf Beitrag Nr.: 34.075.048 von ballard1 am 12.05.08 12:25:09keiner mehr investiert?
Heute mal minus 29 % auf 7,30 US.
Was ist los heute mit AFFY ?
Was ist los heute mit AFFY ?
Antwort auf Beitrag Nr.: 34.589.174 von Fricko am 25.07.08 18:41:02http://sacramento.bizjournals.com/sacramento/stories/2008/07…
Hallo,
Bin in Affymetrix unter 3 dollar eingestiegen,keiner mehr eine Meinung zu diesem wert
? Wie wird es nun weitergehen ? Ich denke mal Affymetrix hat die konkurrenz durch Illumina gut im Griff,wir werden wieder weitaus höhere notierungen sehen,was meint ihr 
?
MFG
ChalifKhan
Bin in Affymetrix unter 3 dollar eingestiegen,keiner mehr eine Meinung zu diesem wert
? Wie wird es nun weitergehen ? Ich denke mal Affymetrix hat die konkurrenz durch Illumina gut im Griff,wir werden wieder weitaus höhere notierungen sehen,was meint ihr 
?MFG
ChalifKhan
Hier mal der Chart!
Sieht nicht schlecht aus!
http://stockcharts.com/h-sc/ui?s=AFFX&p=D&yr=0&mn=3&dy=0&id=…
Sieht nicht schlecht aus!
http://stockcharts.com/h-sc/ui?s=AFFX&p=D&yr=0&mn=3&dy=0&id=…
Antwort auf Beitrag Nr.: 36.247.941 von Lucky72 am 21.12.08 20:04:22Der Kurs befindet sich in einem leichten Aufwärtstrend!
Die Zahlen für das 4Q dürften ausschlaggeben für den weiteren Kursverlauf sein!
Nur meine Meinung!
Die Zahlen für das 4Q dürften ausschlaggeben für den weiteren Kursverlauf sein!
Nur meine Meinung!
Antwort auf Beitrag Nr.: 36.247.978 von Lucky72 am 21.12.08 20:13:25
Das sieht ja richtig gut aus!
Antwort auf Beitrag Nr.: 36.337.010 von Lucky72 am 08.01.09 22:18:16Affymetrix to Webcast Presentation at JPMorgan Healthcare Conference
Date : 01/08/2009 @ 4:00PM
Source : Business Wire
Stock : Affymetrix Inc. (AFFX)
Quote : 3.58 0.24 (7.19%) @ 8:00PM
Affymetrix to Webcast Presentation at JPMorgan Healthcare Conference
Affymetrix Inc. (NASDAQ:AFFX) today announced that Kevin M. King, president and chief executive officer, will provide a company overview at the JPMorgan Healthcare Conference on January 15th in San Francisco, CA. A live webcast of the presentation will take place at 10:00 a.m. PT.
To access both the live and archived webcasts, please go to www.affymetrix.com and click on the "Investors" link under the “Resources for” dropdown. An archived webcast of the presentation will be available for 30 days.
About Affymetrix Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 14,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-looking Statements All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
Date : 01/08/2009 @ 4:00PM
Source : Business Wire
Stock : Affymetrix Inc. (AFFX)
Quote : 3.58 0.24 (7.19%) @ 8:00PM
Affymetrix to Webcast Presentation at JPMorgan Healthcare Conference
Affymetrix Inc. (NASDAQ:AFFX) today announced that Kevin M. King, president and chief executive officer, will provide a company overview at the JPMorgan Healthcare Conference on January 15th in San Francisco, CA. A live webcast of the presentation will take place at 10:00 a.m. PT.
To access both the live and archived webcasts, please go to www.affymetrix.com and click on the "Investors" link under the “Resources for” dropdown. An archived webcast of the presentation will be available for 30 days.
About Affymetrix Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 14,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-looking Statements All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
Nachdem sie wieder ein Stück zurückgekommen ist und auf der 38-T-Linie aufgesetzt hat, wieder positive chartsignale. Lohnt vielleicht einen Blick?
Antwort auf Beitrag Nr.: 36.447.504 von doppelkeks am 26.01.09 10:09:43hat sich GUT gemacht, wenn ich meine Frage einmal selbst beantworten soll
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,33 | |
| -3,45 | |
| +2,30 | |
| -1,03 | |
| -0,15 | |
| +0,57 | |
| +0,09 | |
| -0,04 | |
| +0,12 | |
| -0,64 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 200 | ||
| 184 | ||
| 132 | ||
| 70 | ||
| 29 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 26 |
